Your session is about to expire
← Back to Search
CAR T-cell Therapy
RAPA-201 Autologous T cells for Multiple Myeloma
Phase 2
Waitlist Available
Research Sponsored by Rapa Therapeutics LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up one (1) year after last dose of rapa-201 cells.
Awards & highlights
Study Summary
This trial is testing a new treatment for adults with multiple myeloma who have not responded to other treatments.
Eligible Conditions
- Relapsed or Refractory Multiple Myeloma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ one (1) year after last dose of rapa-201 cells.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one (1) year after last dose of rapa-201 cells.
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Overall response rate
Secondary outcome measures
Effect in Quality of Life
Effect of therapy on disease control
Other outcome measures
Immune reconstitution
Trial Design
1Treatment groups
Experimental Treatment
Group I: Administration of RAPA-201 cellsExperimental Treatment1 Intervention
Find a Location
Who is running the clinical trial?
Rapa Therapeutics LLCLead Sponsor
4 Previous Clinical Trials
64 Total Patients Enrolled
Medical College of WisconsinOTHER
609 Previous Clinical Trials
1,162,574 Total Patients Enrolled
16 Trials studying Multiple Myeloma
1,699 Patients Enrolled for Multiple Myeloma
Daniel Fowler, M.D.Study DirectorRapa Therapeutics LLC
3 Previous Clinical Trials
64 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- Your high blood pressure is not well managed.You have received a stem cell transplant from another person in the past.You have another type of cancer, except for non-melanoma skin cancer.You have a condition called systemic AL Amyloidosis that affects important organs in your body. Just finding amyloid deposits in the bone marrow or within a plasmacytoma is not enough to be considered organ involvement.You have never had a problem with bleeding too much or having bleeding inside your body.You have severe, uncontrolled chest pain or heart disease.You had a stroke in the past 6 months before joining the study.You have severe heart failure that significantly limits your ability to do regular activities.You have a known disease affecting your brain or spinal cord.Your doctor thinks you have less than 4 months to live.
Research Study Groups:
This trial has the following groups:- Group 1: Administration of RAPA-201 cells
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is this clinical investigation accepting new participants?
"The clinical trial is presently seeking participants, with an initial posting date of December 2nd 2020 and the most recent update on 28th December 2021. This information can be found on clinicialtrials.gov."
Answered by AI
What is the sample size of this clinical trial?
"Affirmative. The information displayed on clinicaltrials.gov indicates that this medical study, which was originally posted on December 2nd 2020 is actively recruiting volunteers. 27 participants are needed to be sourced from 1 dedicated research centre."
Answered by AI
Has the US Food and Drug Administration (FDA) endorsed RAPA-201 Autologous T cells?
"The safety of RAPA-201 Autologous T cells was rated as a 2, indicating that there is some evidence suggesting it can be safely administered but no efficacy data available yet."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger